Abstract: The present invention relates to compounds derived from steroids of the general formula (I) wherein L represents a linker and R# represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).

Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

Abstract: The present invention describes tripodal catechol derivatives with an adamantyl basic framework for the functionalization of surfaces, methods for their production and use. The remaining fourth bridgehead position is easily suitable to be further functionalised via so-called click reactions, by way of example with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents.

Abstract: The present invention discloses an immunological test for the detection and specific determination of autoantibodies against testicular antigens which are associated with inflammation-related fertility disorders of male mammals in a biological sample of a male mammal, in particular the detection of testicular ER-60 autoantibodies and/or transferrin autoantibodies. The immunological test is utilized to detect the presence of immunologically-caused and infection-related infertility in male mammals, particularly in humans.

Abstract: The present invention relates to compounds derived from steroids of the general formula (I) wherein L represents a linker and R# represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).

Abstract: The current invention relates to a method of making metal oxide nanoparticles comprising the reaction of—at least one metal oxide precursor (P) containing at least one metal (M) with—at least one monofunctional alcohol (A) wherein the hydroxy group is bound to a secondary, tertiary or alpha-unsaturated carbon atom—in the presence of at least one aliphatic compound (F) according to the formula Y1—R1—X—R2—Y2, wherein—R1 and R2 each are the same or different and independently selected from aliphatic groups with from 1 to 20 carbon atoms, —Y1 and Y2 each are the same or different and independently selected from OH, NH2 and SH, and —X is selected from the group consisting of chemical bond, —O—, —S—, —NR3—, and CR4R5, wherein R3, R4 and R5 each are the same or different and represent a hydrogen atom or an aliphatic group with from 1 to 20 carbon atoms which optionally carries functional groups selected from OH, NH2 and SH.

Abstract: The invention at hand concerns a novel class of gas sensors, in particular for hydrogen or hydrogen-containing fluids (gases or liquids), such as hydrocarbons, hydrogen sulphides or more complex gas mixtures or gas compositions which contain hydrogen or hydrogen compounds.

Abstract: The present invention provides nano-, meso- and micro-polymer particles which are able to bind pathogenic proteins penetrating into the lining layer of the lung. Known pathogenic proteins in the pulmonary lining layer are negatively charged. These proteins damage the pulmonary surfactant system which is essential to maintain a low surface tension in the lung and thus a functional respiration. Polymer particles of this invention have a diameter between 20 nm and 10 ?m, are water-insoluble, have a positive surface charge and a low surface hydrophobicity. The isoelectric point of said particles is greater than 5 to that said particles are present in the lining layer of the lung as positively charged particles, and at the same time higher than the isoelectric point of the pathogenic protein to be bound. Polymer particles of this invention can for example be prepared using the precipitation or emulsion method.

Abstract: The invention relates to supports consisting of nanoscalar polymer fibers, polymer tubes or hollow fibers for the application and targeted and/or delayed release of ingredients, in particular, agricultural active ingredients. The invention also relates to a method and a device for the production of supports of this type in a charged or empty state. The method and device use electrospinning technology.

Abstract: The invention relates to a novel optical function layer and its production, the function layer imparting to materials coated with it protection against uv radiation while transmitting electromagnetic radiation of larger wavelengths. The function layer of the invention and the manufacturing method of the invention offer advantages over the state of the art by allowing very accurate and precise adjustability in the uv range of the relatively sharp absorption constant.

Abstract: The invention at hand describes Cu-(II)-oxygen adduct complexes, which are stable at room temperature, as well as methods for their production. In this, compounds of the general formula [L-Cu—O—O—Cu-L](BAr4)2 are concerned. Here, BAr4? is a tetraarylborate anion, selected from tetraphenylborate and tetrakis(3,5-trifluoromethyl)phenylborate. L represents a tripodal tetradentate ligand, wherein, each of the four binding sites of the tripodal tetradentate ligand is a nitrogen atom. Each of the three podal ligands is suitable for comprising an aliphatic amine or a nitrogen-containing heteroaromatic compound independently of one another. A bridge of one to four carbon atoms is located between the central nitrogen atom and the nitrogen atom of each of the podal ligands. The Cu-(II)-oxygen adduct complexes according to the present invention are produced, by initially reacting the ligand L with a Cu-(I) salt to [Cu-L]X.

Abstract: Disclosed herein is a device for the application of agricultural active agents, wherein the device is suitable to be brought to the site of action in a manner temporally and spatially separated from the production process, and comprises a dispenser and non-water-soluble nanofibers and/or mesofibers charged with agricultural active agents. The polymers from which the nanofibers and/or mesofibers are made are preferably biodegradable. The agricultural active agents are selected from fungicides, herbicides, batericides, plant growth regulators and plant nutrients. These are preferably pheromones, kairomones and signaling substances. Furthermore, a method for the production of this device is disclosed, wherein the nanofibers and/or mesofibers charged with active agents are produced via electrospinning. The device is suitable to be used to bring agricultural active agents to the site of action in a manner temporally and spatially separated from the production of this device.

Abstract: A rapid, safe method for predicting sepsis, or a condition similar to sepsis, in a mammal is disclosed, which comprises the following steps: I) isolating RNA from a biological sample of a mammal; ii) labeling the isolated RNA of step I) with a detectable marker; iii) hybridizing the labeled isolated RNA of step ii) with at least one DNA of genes Seq.-ID 1 to Seq.-ID 6705 (Table 1), which is spotted onto a microarray and which is a sepsis-specific gene or gene fragment, under the reaction conditions for hybridizations; iv) quantitatively recording labeling signals of the hybridized RNA of step iii) in an expression profile; v) comparing the expression profile of step iv) with a control sample with respect to a stronger or weaker expression of genes or gene fragments which are specific for sepsis; and vi) combining the expression profile of step v) with protein- and metabolite patterns of the biological sample.

Abstract: The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 ?m and lengths of 1 ?m to several meters. The invention further relates to a method for producing said composite materials.

Abstract: The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other fungi.

Abstract: The present invention concerns a method for the species-specific and quantitative detection of CNS tissue in meat and meat products of the ruminant species bovine, ovine and caprine or porcine by a real-time PCR method, using glial fibrillary acidic protein (GFAP) messenger (m)-RNA. The method is very reliable and can be easily conducted even in heat-treated samples.

Abstract: The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well as to a method for their production. The invention further refers to a pharmaceutical composition comprising such a fusion protein and to pharmacological uses of an inventive fusion protein for the prevention and/or treatment of inflammatory and interstitial lung diseases.

Abstract: Carriers for the production and targeted and/or delayed release, particularly of agricultural active substances, as well as a method for the output and a device for the production of such carriers in a loaded or unloaded state are proposed. The method and the device use the technology of electrospinning.

Abstract: The invention relates to supports consisting of nanoscalar polymer fibres, polymer tubes or hollow fibres for the application and targeted and/or delayed release of ingredients, in particular, agricultural active ingredients. The invention also relates to a method and a device for the production of supports of this type in a charged or empty state. The method and device use electrospinning technology.

Abstract: The invention relates to supports consisting of nanoscalar polymer fibres, polymer tubes or hollow fibres for the application and targeted and/or delayed release of ingredients, in particular, agricultural active ingredients. The invention also relates to a method and a device for the production of supports of this type in a charged or empty state. The method and device use electrospinning technology.